The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial—Study Design and Protocol

Haluzík, Martin

DOI: https://doi.org/10.1007/s13300-024-01582-x

2024-04-25

Diabetes Therapy

Abstract:Multiple daily injection insulin regimen (MDI) represents the most intensive insulin regimen used in the management of people with type 2 diabetes (PwT2D). Its efficacy regarding glycaemic control is counterbalanced by the increased risk of hypoglycaemia, frequently observed tendency to weight gain and necessity for frequent glucose monitoring. Recent introduction of novel antidiabetic medications with pleiotropic effects reaching far beyond the reduction of glycaemia (HbA1c), such as the glucagon-like peptide 1 receptor agonist (GLP-1 RA), has significantly widened the therapeutic options available for management of T2D. Consequently, there is currently a substantial number of PwT2D for whom the MDI regimen was initiated at a time when no other options were available. Yet, in present times, these individuals could benefit from simplified insulin regimens ideally taking advantage of the beneficial effects of the novel classes of antidiabetic medications. iGlarLixi (Suliqua ® ) is a once-daily fixed-ratio combination of basal insulin analogue glargine 100 U/ml and a GLP-1 RA lixisenatide.

endocrinology & metabolism

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper presents the design and protocol of a randomized controlled trial named IDEAL (Insulin therapy DE - intensificAtion with iglarLixi). The study aims to evaluate the efficacy and safety of simplifying the multi - daily - injection insulin (MDI) regimen, specifically comparing the use of the once - daily fixed - ratio combination drug iGlarLixi (Suliqua®) with the continuation of the MDI regimen.

**Specific problems include**:

1. **Blood glucose control**:
- Compare the effects of MDI treatment simplification (i.e., using iGlarLixi) and the continuation of the MDI regimen on blood glucose control (HbA1c levels).

2. **Risk of hypoglycemia**:
- Evaluate the incidence of hypoglycemic events after simplifying MDI treatment.

3. **Weight and body composition**:
- Compare the effects of the two treatment regimens on weight and body composition.

4. **Quality of life**:
- Evaluate the effects of the two treatment regimens on patients' quality of life through patient - reported outcomes (such as the Diabetes Treatment Satisfaction Questionnaire, Hypoglycemia Attitude and Behavior Scale, etc.).

5. **Safety**:
- Evaluate the overall safety after simplifying MDI treatment, including the incidence of adverse events and serious adverse events.

### Background

- **MDI regimen**: Multi - daily - injection insulin treatment is the most complex insulin treatment regimen for managing type 2 diabetes patients. Although it is very effective in blood glucose control, it has problems such as a high risk of hypoglycemia, a significant tendency to gain weight, and the need for frequent blood glucose monitoring and insulin dose adjustment.
- **New antidiabetic drugs**: In recent years, new antidiabetic drugs with multiple effects have emerged, such as GLP - 1 receptor agonists (GLP - 1 RA). These drugs can not only lower blood glucose but also improve other metabolic indicators.
- **iGlarLixi**: iGlarLixi is a once - daily fixed - ratio combination drug that contains the basal insulin analogue insulin glargine 100 U/ml and the GLP - 1 receptor agonist lixisenatide. This combination drug is expected to simplify the insulin treatment regimen while maintaining or improving blood glucose control effects and reducing the risks of hypoglycemia and other side effects.

### Research design

- **Study type**: Six - center, open - label, parallel - group, active - controlled, phase IV randomized controlled trial.
- **Study population**: Approximately 100 type 2 diabetes patients who meet the inclusion criteria.
- **Interventions**: Participants are randomly assigned to two groups, one group continues to use the MDI regimen, and the other group switches to using iGlarLixi.
- **Primary endpoint**: The change in HbA1c levels from baseline to 24 weeks (6 months).
- **Secondary endpoints**: Include continuous glucose monitoring (CGM) - related indicators, self - monitored blood glucose data, changes in weight and body composition, quality of life assessment, and safety assessment.

### Conclusion

The IDEAL trial is the first randomized controlled trial to formally evaluate the efficacy and safety of using iGlarLixi to simplify the intensive insulin treatment regimen. The results of this trial will provide a solid evidence base for simplifying the MDI regimen in clinical practice, with the ultimate goal of benefiting type 2 diabetes patients currently receiving complex insulin treatment regimens.